

TEKLA HEALTHCARE INVESTORS
Form N-PX
August 20, 2018

**UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION**

OMB APPROVAL
OMB Number: 3235-0582
Expires: March 31, 2021
Estimated average burden
hours per response.....7.2

Washington, D.C. 20549

FORM N-PX

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number 811- 04889

Tekla Healthcare Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA
(Address of principal executive offices)

02110
(Zip code)

Laura Woodward

Tekla Healthcare Investors

100 Federal Street, 19th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Date of reporting period: **7/1/17-6/30/18**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, not later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Item 1. Proxy Voting Record.

*Vote Summary***ABBOTT LABORATORIES**

Security	002824100	Meeting Type	Annual
Ticker Symbol	ABT	Meeting Date	27-Apr-2018
Record Date	28-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	R.J. Alpern	For	For
	2	R.S. Austin	For	For
	3	S.E. Blount	For	For
	4	E.M. Liddy	For	For
	5	N. McKinstry	For	For
	6	P.N. Novakovic	For	For
	7	W.A. Osborn	For	For
	8	S.C. Scott III	For	For
	9	D.J. Starks	For	For
	10	J.G. Stratton	For	For
	11	G.F. Tilton	For	For
	12	M.D. White	For	For
2.	Ratification of Ernst & Young LLP as Auditors	Management	For	For
3.	Say on Pay - An Advisory Vote to Approve Executive Compensation	Management	For	For
4.	Shareholder Proposal - Independent Board Chairman	Shareholder	For	Against

ABBVIE INC.

Security	00287Y109	Meeting Type	Annual
Ticker Symbol	ABBV	Meeting Date	04-May-2018
Record Date	07-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Roxanne S. Austin	For	For
	2	Richard A. Gonzalez	For	For
	3	Rebecca B. Roberts	For	For
	4	Glenn F. Tilton	For	For
2.	Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2018	Management	For	For
3.	Say on Pay - An advisory vote on the approval of executive compensation	Management	For	For
4.	Say When on Pay - An advisory vote on the frequency of the advisory vote to approve executive compensation	Management	1 Year	For
5.		Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

	Approval of a management proposal regarding amendment of the certificate of incorporation for the annual election of directors			
6.	Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting	Management	For	For
7.	Stockholder Proposal - to Issue an Annual Report on Lobbying	Shareholder	Against	For
8.	Stockholder Proposal - to Separate Chair and CEO	Shareholder	For	Against
9.	Stockholder Proposal - to Issue an Annual Compensation Committee Report on Drug Pricing	Shareholder	Against	For

AC IMMUNE SA

Security	H00263105	Meeting Type	Special
Ticker Symbol	ACIU	Meeting Date	27-Apr-2018
Record Date	13-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	In the event that at the Extraordinary Shareholders Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors	Management	For	N/A
2.A	Election of Douglas Williams as Member to the Board of Directors	Management	For	N/A
2.B	Election of Douglas Williams to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
3.a	Vote on Total Non-Performance-Related Compensation for the new Member of the Board of Directors from 27 April 2018 to 30 June 2018	Management	For	N/A
3.b	Vote on Equity for the new Member of the Board of Directors	Management	For	N/A
4.a	Share Capital Increase for Institutional Investors	Management	For	N/A
4.b	Share Capital Increase for Current Shareholders	Management	For	N/A

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

AC IMMUNE SA

Security Ticker Symbol Record Date	H00263105 ACIU 23-May-2018	Meeting Type Meeting Date	Annual 06-Jul-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
A.	In the event that at the Annual General Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors	Management	For	N/A
1.	Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2017	Management	For	N/A
2.	Appropriation of Loss	Management	For	N/A
3.	Discharge of the Members of the Board of Directors and the Executive Committee	Management	For	N/A
4a.	Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2018 to 30 June 2019	Management	For	N/A
4b.	Vote on Equity for Members of the Board of Directors	Management	For	N/A
4c.	Vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2018 to 30 June 2019	Management	For	N/A
4d.	Vote on Total Variable Compensation for Members of the Executive Committee for the current year 2018	Management	For	N/A
4e.	Vote on Equity for Members of the Executive Committee	Management	For	N/A
5a.	Re-election of Martin Velasco as member and Chairman of the Board of Directors	Management	For	N/A
5b.	Re-election of Peter Bollmann as the Member of the Board	Management	For	N/A
5c.	Re-election of Friedrich von Bohlen as the Member of the Board	Management	For	N/A
5d.	Re-election of Andrea Pfeifer as the Member of the Board	Management	For	N/A
5e.	Re-election of Detlev Riesner as the Member of the Board including granting an exception to the age limit	Management	For	N/A
5f.	Re-election of Tom Graney as the Member of the Board	Management	For	N/A
5g.	Re-election of Douglas Williams as the Member of the Board	Management	For	N/A
5h.	Election of Werner Lanthaler as the Member of the Board	Management	For	N/A
6a.	Re-election of Tom Graney to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
6b.	Re-election of Martin Velasco to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
6c.	Re-election of Doug Williams to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
7.	Re-election of the independent proxy Bugnion Ballansat Ehrler, represented by Gerald Virieux, avocat, Geneva	Management	For	N/A
8.	Election of the Auditors, PricewaterhouseCoopers SA, Pully	Management	For	N/A
9a.	Share Capital Increase for Institutional Investors	Management	For	N/A
9b.	Share Capital Increase for Current Shareholders	Management	For	N/A

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

ACADIA HEALTHCARE COMPANY, INC.

Security	00404A109	Meeting Type	Annual
Ticker Symbol	ACHC	Meeting Date	03-May-2018
Record Date	09-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: E. Perot Bissell	Management	For	For
1.2	Election of Director: Vicky B. Gregg	Management	For	For
2.	Advisory vote on the compensation of the Company's named executive officers as presented in the Proxy Statement.	Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ACADIA PHARMACEUTICALS INC.

Security	004225108	Meeting Type	Annual
Ticker Symbol	ACAD	Meeting Date	06-Jun-2018
Record Date	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Julian Baker		For	For
	2 Stephen Biggar, M.D PhD		For	For
	3 Daniel Soland		For	For
2.	To approve an amendment to our 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ACCELERON PHARMA INC.

Security	00434H108	Meeting Type	Annual
Ticker Symbol	XLRN	Meeting Date	06-Jun-2018
Record Date	09-Apr-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Habib J. Dable	Management	For	For
1b.	Election of Class II Director: Terrence C. Kearney	Management	For	For
1c.	Election of Class II Director: Karen L. Smith, M.D., Ph.D.	Management	For	For
2.	To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the proxy statement.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

AKEBIA THERAPEUTICS, INC.

Security	00972D105	Meeting Type	Annual
Ticker Symbol	AKBA	Meeting Date	14-Jun-2018
Record Date	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Michael D. Clayman	For	For
	2	Duane Nash	For	For
	3	Ronald C. Renaud, Jr.	For	For
	4	John P. Butler	For	For
	5	Muneer A. Satter	For	For
	6	Michael S. Wyzga	For	For
2.	Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ALBIREO PHARMA INC.

Security	01345P106	Meeting Type	Annual
Ticker Symbol	ALBO	Meeting Date	08-Jun-2018
Record Date	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Ronald H.W. Cooper	For	For
	2	Anne Klibanski, M.D.	For	For
	3	Stephanie S. Okey, M.S.	For	For
2.	To approve the Albireo Pharma, Inc. 2018 Equity Incentive Plan.	Management	For	For
3.	To approve the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan.	Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as Albireo's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ALDER BIOPHARMACEUTICALS, INC.

Security	014339105	Meeting Type	Annual
Ticker Symbol	ALDR	Meeting Date	23-May-2018
Record Date	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
------	----------	-------------	------	------------------------

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

1.	DIRECTOR		Management		
	1	Paul B. Cleveland		For	For
	2	Stephen M. Dow		For	For
	3	A. Bruce Montgomery		For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.		Management	For	For
3.	To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.		Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

ALEXION PHARMACEUTICALS, INC.

Security	015351109	Meeting Type	Annual
Ticker Symbol	ALXN	Meeting Date	08-May-2018
Record Date	12-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Felix J. Baker	For	For
	2	David R. Brennan	For	For
	3	Christopher J. Coughlin	For	For
	4	Deborah Dunsire	For	For
	5	Paul A. Friedman	For	For
	6	Ludwig N. Hantson	For	For
	7	John T. Mollen	For	For
	8	Francois Nader	For	For
	9	Judith A. Reinsdorf	For	For
	10	Andreas Rummelt	For	For
2.	Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.	Management	For	For
3.	Approval of a non-binding advisory vote of the 2017 compensation paid to Alexion's named executive officers.	Management	For	For
4.	To request the Board to require an independent Chairman.	Shareholder	For	Against

ALKERMES PLC

Security	G01767105	Meeting Type	Annual
Ticker Symbol	ALKS	Meeting Date	23-May-2018
Record Date	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Floyd E. Bloom, M.D.	Management	For	For
1b.	Election of Director: Nancy L. Snyderman, M.D.	Management	For	For
1c.	Election of Director: Nancy Wysenski	Management	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	To hold a non-binding, advisory vote, on the frequency of future advisory votes on the compensation paid to the Company's named executive officers.	Management	1 Year	For
4.	To ratify, on a non-binding, advisory basis, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board of Directors to set the independent auditor and accounting firm's remuneration.	Management	For	For
5.	To approve the Alkermes plc 2018 Stock Option and Incentive plan.	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

ALLERGAN PLC

Security	G0177J108	Meeting Type	Annual
Ticker Symbol	AGN	Meeting Date	02-May-2018
Record Date	06-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Nesli Basgoz, M.D.	Management	For	For
1b.	Election of Director: Paul M. Bisaro	Management	For	For
1c.	Election of Director: Joseph H. Boccuzzi	Management	For	For
1d.	Election of Director: Christopher W. Bodine	Management	For	For
1e.	Election of Director: Adriane M. Brown	Management	For	For
1f.	Election of Director: Christopher J. Coughlin	Management	For	For
1g.	Election of Director: Carol Anthony (John) Davidson	Management	For	For
1h.	Election of Director: Catherine M. Klema	Management	For	For
1i.	Election of Director: Peter J. McDonnell, M.D.	Management	For	For
1j.	Election of Director: Patrick J. O. Sullivan	Management	For	For
1k.	Election of Director: Brenton L. Saunders	Management	For	For
1l.	Election of Director: Fred G. Weiss	Management	For	For
2.	To approve, in a non-binding vote, Named Executive Officer compensation.	Management	For	For
3.	To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the Board of Directors, acting through its Audit and Compliance Committee, to determine PricewaterhouseCoopers LLP's remuneration.	Management	For	For
4.	To renew the authority of the directors of the Company (the Directors) to issue shares.	Management	For	For
5A.	To renew the authority of the Directors to issue shares for cash without first offering shares to existing shareholders.	Management	For	For
5B.	To authorize the Directors to allot new shares up to an additional 5% for cash in connection with an acquisition or other capital investment.	Management	For	For
6.	To consider a shareholder proposal requiring an independent Board Chairman, if properly presented at the meeting.	Shareholder	Against	For

ALLIQUA BIOMEDICAL, INC.

Security	019621200	Meeting Type	Special
Ticker Symbol	ALQA	Meeting Date	13-Sep-2017
Record Date	26-Jul-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	TO RATIFY THE FILING AND EFFECTIVENESS OF THE CERTIFICATE OF AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF	Management	For	For

INCORPORATION FILED WITH THE SECRETARY OF STATE OF THE STATE OF DELAWARE ON MAY 6, 2016 AND THE INCREASE IN THE NUMBER OF SHARES OF AUTHORIZED COMMON STOCK EFFECTED THEREBY.

- | | | | | |
|----|--|------------|-----|-----|
| 2. | TO APPROVE THE PROPOSAL TO AUTHORIZE THE COMPANY S BOARD OF DIRECTORS, IN ITS DISCRETION BUT PRIOR TO THE ANNUAL MEETING OF THE COMPANY S STOCKHOLDERS IN 2018, TO AMEND THE COMPANY S CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY S COMMON STOCK, AT A RATIO IN THE RANGE OF ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL). | Management | For | For |
| 3. | TO APPROVE AN ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF ANY OF THE FOREGOING PROPOSALS. | Management | For | For |

ALLIQUA BIOMEDICAL, INC.

Security	019621309	Meeting Type	Special
Ticker Symbol	ALQA	Meeting Date	27-Apr-2018
Record Date	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	A proposal to approve the Asset Purchase Agreement, the Asset Sale Transaction and the other transactions contemplated by the Asset Purchase Agreement (the Asset Sale Proposal).	Management	For	For
2.	A proposal to approve, on an advisory, non-binding basis, certain compensation that has, will or may be paid or become payable to the Company's named executive officers in connection with the asset sale (the Advisory Proposal).	Management	For	For
3.	A proposal to adjourn or postpone the Special Meeting of stockholders, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of the Asset Sale Proposal (the Adjournment Proposal).	Management	For	For

ALLIQUA BIOMEDICAL, INC.

Security	019621309	Meeting Type	Annual
Ticker Symbol	ALQA	Meeting Date	26-Jun-2018
Record Date	03-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 David Johnson		For	For
	2 Joseph Leone		For	For
	3 Gary Restani		For	For
	4 Jeffrey Sklar		For	For
	5 Mark Wagner		For	For
2.	Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ALNYLAM PHARMACEUTICALS, INC.

Security	02043Q107	Meeting Type	Annual
Ticker Symbol	ALNY	Meeting Date	10-May-2018
Record Date	15-Mar-2018		

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Dennis A. Ausiello, M.D.	Management	For	For
1b.	Election of Class II Director: John K. Clarke	Management	For	For
1c.	Election of Class II Director: Marsha H. Fanucci	Management	For	For
1d.	Election of Class II Director: David E.I. Pyott	Management	For	For
2.	To approve the 2018 Stock Incentive Plan.	Management	For	For
3.	To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.	Management	For	For
4.	To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2018.	Management	For	For

AMARIN CORPORATION PLC

Security	02311206	Meeting Type	Annual
Ticker Symbol	AMRN	Meeting Date	14-May-2018
Record Date	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect Mr. John F. Thero as a director.	Management	For	For
2.	To re-elect Mr. Patrick J. O. Sullivan as a director.	Management	For	For
3.	To hold an advisory (non-binding) vote to approve the compensation of the Company's named executive officers as described in full in the accompanying Proxy Statement.	Management	For	For
4.	To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors remuneration as described in the accompanying Proxy Statement.	Management	For	For

AMGEN INC.

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	22-May-2018
Record Date	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Dr. Wanda M. Austin	Management	For	For
1b.	Election of Director: Mr. Robert A. Bradway	Management	For	For
1c.	Election of Director: Dr. Brian J. Druker	Management	For	For
1d.	Election of Director: Mr. Robert A. Eckert	Management	For	For
1e.	Election of Director: Mr. Greg C. Garland	Management	For	For
1f.	Election of Director: Mr. Fred Hassan	Management	For	For
1g.	Election of Director: Dr. Rebecca M. Henderson	Management	For	For
1h.	Election of Director: Mr. Frank C. Herringer	Management	For	For
1i.	Election of Director: Mr. Charles M. Holley, Jr.	Management	For	For
1j.	Election of Director: Dr. Tyler Jacks	Management	For	For
1k.	Election of Director: Ms. Ellen J. Kullman	Management	For	For
1l.	Election of Director: Dr. Ronald D. Sugar	Management	For	For
1m.	Election of Director: Dr. R. Sanders Williams	Management	For	For
2.	Advisory vote to approve our executive compensation.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2018.	Management	For	For
4.	Stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation.	Shareholder	Against	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

AMICUS THERAPEUTICS, INC.

Security	03152W109	Meeting Type	Annual
Ticker Symbol	FOLD	Meeting Date	07-Jun-2018
Record Date	16-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Donald J. Hayden, Jr.		For	For
	2 Craig Wheeler		For	For
2.	Proposal to approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value \$0.01 per share, that we are authorized to issue from 250,000,000 to 500,000,000	Management	For	For
3.	Approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018	Management	For	For
5.	Approval, on an advisory basis, the Company's executive compensation	Management	For	For

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

AMPHIVENA THERAPEUTICS, INC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	20-Dec-2017
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Amended and Restated Certificate of Incorporation	Management	For	For
2.	Approval of Bridge Loan and Waiver of Right of First Offer	Management	For	For
3.	Omnibus Resolutions	Management	For	For

ANTHEM, INC.

Security	036752103	Meeting Type	Annual
Ticker Symbol	ANTM	Meeting Date	16-May-2018
Record Date	09-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Lewis Hay, III	Management	For	For
1b.	Election of Director: Julie A. Hill	Management	For	For
1c.	Election of Director: Antonio F. Neri	Management	For	For
1d.	Election of Director: Ramiro G. Peru	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2018.	Management	For	For
3.	Advisory vote to approve the compensation of our named executive officers.	Management	For	For
4.	To approve proposed amendments to our Articles of Incorporation to allow shareholders owning 20% or more of our common stock to call special meetings of shareholders.	Management	For	For
5.	Shareholder proposal to allow shareholders owning 10% or more of our common stock to call special meetings of shareholders.	Shareholder	Against	For

ARENA PHARMACEUTICALS, INC.

Security	040047607	Meeting Type	Annual
Ticker Symbol	ARNA	Meeting Date	13-Jun-2018
Record Date	24-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
-------------	-----------------	--------------------	-------------	-------------------------------

1.

DIRECTOR

Management